股本结构
单位：万股
| 公告日期 | 2026-03-26 | 2026-01-28 | 2025-11-07 | 2025-11-07 | 2025-03-25 | 2024-11-12 |
|---|---|---|---|---|---|---|
| 证券总股本 | 205.69 | 172.99 | 137.31 | 136.74 | 136.70 | 136.49 |
| 普通股本 | 205.69 | 172.99 | 137.31 | 136.74 | 136.70 | 136.49 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-03-19 | 2026-01-23 | 2025-10-31 | 2025-09-30 | 2025-03-19 | 2024-09-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-03-26 | 205.69 | 未披露 | 定期报告 | 2026-03-19 |
| 2026-01-28 | 172.99 | 未披露 | 定期报告 | 2026-01-23 |
| 2025-11-07 | 137.31 | 未披露 | 定期报告 | 2025-10-31 |
| 2025-11-07 | 136.74 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of shares related to employee stock purchase plan
|
2025-09-30 |
| 2025-03-25 | 136.70 | 未披露 | 定期报告 | 2025-03-19 |
| 2024-11-12 | 136.49 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of shares related to employee stock purchase plan
|
2024-09-30 |
| 2024-08-13 | 136.28 | 未披露 | 定期报告 | 2024-06-30 |
| 2024-05-16 | 136.29 | 未披露 | 定期报告 | 2024-05-01 |
| 2024-03-28 | 136.28 | 未披露 | 定期报告 | 2024-03-21 |
| 2024-03-28 | 128.53 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of shares related to March 2023 pre-funded warrants exercise
Issuance of shares related to reverse stock split
Issuance of shares related to August 2022 pre-funded warrants exercise
Issuance of shares related to March 2023 PIPE
Issuance of shares related to employee stock purchase plan
|
2023-12-31 |
| 2023-11-09 | 111.03 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of shares related to employee stock purchase plan
|
2023-09-30 |
| 2023-08-10 | 110.84 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of shares related to March 2023 pre-funded warrants exercise
Issuance of shares related to reverse stock split
|
2023-06-30 |
| 2023-05-15 | 95.04 | 未披露 | 定期报告 | 2023-05-08 |
| 2023-03-30 | 85.76 | 未披露 | 定期报告 | 2023-03-23 |
| 2023-02-28 | 61.61 | 未披露 |
更多>>
On February 27, 2023, Arcadia Biosciences, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-40 reverse stock split of the outstanding shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), effective as of 12:01 a.m. (Delaware time) on March 1, 2023 (the “Reverse Stock Split”).
|
2023-03-01 |
| 2023-01-06 | 2464.30 | 2.46 | 定期报告 | 2022-12-30 |
| 2022-11-10 | 2464.30 | 未披露 |
更多>>
From June 30, 2022 to September 20, 2022
Issuance of shares related to August 2022 Offering
Issuance of shares related to employee stock purchase plan
|
2022-09-20 |
| 2022-08-16 | 2464.30 | 未披露 |
更多>>
1.Common Stock offered 2,450,000 shares of common stock
2.Unless the company indicate otherwise, all information in this prospectus is based on 22,192,960 shares of common stock outstanding as of August 12, 2022
|
2022-08-16 |
| 2022-08-11 | 2219.30 | 未披露 | 定期报告 | 2022-08-08 |
| 2022-03-31 | 2218.89 | 未披露 | 定期报告 | 2022-03-24 |
| 2022-03-31 | 2218.42 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of shares related to the January 2021 PIPE
Issuance of shares at closing of Arcadia Wellness acquisition
Issuance of shares related to exercise of Service and Performance Warrants
|
2021-12-31 |
| 2021-11-15 | 2218.42 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of shares related to employee stock purchase plan
Issuance of shares related to exercise of Service and Performance Warrants
|
2021-09-30 |
| 2021-08-16 | 2217.37 | 未披露 | 定期报告 | 2021-08-09 |
| 2021-08-16 | 2216.37 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of shares at closing of Arcadia Wellness acquisition
|
2021-06-30 |
| 2021-05-17 | 2133.62 | 未披露 |
更多>>
From December 31, 2020 To March 19, 2021
Issuance of shares related to the January 2021 PIPE
Issuance of shares related to employee stock purchase plan
|
2021-03-19 |
| 2021-02-02 | 2132.76 | 未披露 | 定期报告 | 2021-01-28 |
| 2020-12-22 | 1345.09 | 未披露 |
更多>>
1.Common Stock offered by this prospectus supplement 2,618,658 shares of Common Stock.
2.Unless the company indicate otherwise, all information in this prospectus is based on 10,832,203 shares of Common Stock outstanding as of December 18, 2020.
|
2020-12-22 |
| 2020-11-13 | 1083.22 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of shares related to exercise of March 2018 PIPE
Issuance of shares related to employee stock purchase plan
Shares of common stock issued at closing of ISI transaction
|
2020-09-30 |
| 2020-08-13 | 1069.96 | 未披露 | 定期报告 | 2020-08-07 |
| 2020-08-13 | 1004.64 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of shares related to exercise of June 2018 Warrants
|
2020-06-30 |
| 2020-07-02 | 1004.64 | 未披露 | 定期报告 | 2020-06-23 |
| 2020-05-13 | 865.41 | 未披露 |
更多>>
From December 31, 2019 to March 18, 2020
Issuance of shares related to employee stock purchase plan
|
2020-03-18 |
| 2019-11-06 | 864.61 | 未披露 |
更多>>
from December 31, 2018 to September 30, 2019
Issuance of shares related to employee stock purchase plan
Issuance of shares related to employee stock option exercises
Issuance of shares related to June 2019 Offering
Issuance of shares related to the exercise of warrants issued with the June 2019 offering
Issuance of shares related to September 2019 Offering
|
2019-09-30 |
| 2019-09-10 | 861.61 | 未披露 | 定期报告 | 2019-09-10 |
| 2019-09-09 | 729.73 | 未披露 | 定期报告 | 2019-09-05 |
| 2019-08-14 | 626.70 | 未披露 |
更多>>
from December 31, 2018 to June 14, 2019
Issuance of shares related to employee stock purchase plan
Issuance of shares related to June 2019 Offering
|
2019-06-14 |
| 2019-05-08 | 477.74 | 未披露 |
更多>>
From December 31, 2018 to March 7, 2019
Issuance of shares related to employee stock purchase plan
|
2019-03-07 |
| 2019-04-01 | 477.49 | 未披露 |
更多>>
from December 31, 2017 to December 19, 2018
Issuance of shares related to employee stock option exercises
Issuance of shares related to employee stock purchase plan
Issuance of shares related to Purchase Agreement
Issuance of shares related to June Offering
Issuance of shares related to reverse stock split
|
2018-12-19 |
| 2018-11-07 | 477.49 | 未披露 |
更多>>
from December 31, 2017 to September 30, 2018
Issuance of shares related to employee stock option exercises
Issuance of shares related to employee stock purchase plan
Issuance of shares related to Purchase Agreement
Issuance of shares related to June Offering
Issuance of shares related to reverse stock split
|
2018-09-30 |
| 2018-08-08 | 477.44 | 未披露 |
更多>>
From December 31, 2017 to June 30, 2018
Issuance of shares related to employee stock option exercises
Issuance of shares related to employee stock purchase plan
Issuance of shares related to Purchase Agreement
Issuance of shares related to June Offering
Issuance of shares related to reverse stock split
|
2018-06-30 |
| 2018-05-11 | 338.20 | 未披露 | 定期报告 | 2018-05-09 |
| 2018-05-17 | 338.20 | 未披露 | 定期报告 | 2018-05-08 |
| 2018-05-09 | 297.91 | 未披露 | 定期报告 | 2018-05-04 |
| 2018-05-17 | 261.04 | 未披露 | 定期报告 | 2018-05-03 |
| 2018-05-09 | 248.11 | 未披露 |
更多>>
From December 31, 2017 to March 30, 2018
Issuance of shares related to employee stock option exercises
Issuance of shares related to employee stock purchase plan
Issuance of shares related to securities purchase agreement
Issuance of shares related to reverse stock split
|
2018-03-30 |
| 2018-04-13 | 248.11 | 未披露 | 定期报告 | 2018-03-28 |
| 2018-03-20 | 213.60 | 未披露 | 定期报告 | 2018-03-01 |
| 2018-03-20 | 213.42 | 未披露 |
更多>>
from December 31, 2016 to January 24, 2018
Issuance of shares related to employee stock purchase plan
Exchange of membership interest in unconsolidated entity for common stock
On Janaury19, 2018, Arcadia Biosciences, Inc. held a special meeting of stockholders. At the Special Meeting, the stockholders approved the proposal to amend the Company’s Amended and Restated Certificate of Incorporation, as amended , to effect a reverse stock split of its outstanding common stock at a ratio in the range of one-for-ten to one-for-twenty, to be determined at the discretion of the Board of Directors of the Company.
|
2018-01-24 |
| 2017-11-09 | 4268.31 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-05-10 | 4266.48 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-03-08 | 4450.87 | 未披露 | 定期报告 | 2017-02-28 |
| 2017-03-08 | 4448.77 | 未披露 |
更多>>
From December 31, 2015 to December 31, 2016
Exercise of stock options
Issuance of shares related to employee stock purchase plan
|
2016-12-31 |
| 2016-11-10 | 4447.93 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-08-09 | 4442.21 | 未披露 | 定期报告 | 2016-07-29 |
| 2016-08-09 | 4439.50 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-05-10 | 4425.29 | 未披露 | 定期报告 | 2016-04-29 |
| 2016-04-22 | 4425.17 | 未披露 | 定期报告 | 2016-04-11 |
| 2016-05-10 | 4424.89 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-08 | 4422.06 | 未披露 | 定期报告 | 2016-03-01 |
| 2016-03-08 | 4418.42 | 未披露 |
更多>>
From December 31, 2014 to December 31, 2015
Exercise of stock options
Preferred stock conversion to common stock upon the IPO
Issuance of common stock upon the IPO, net of issuance costs of $9,799
The 1-for-4 reverse split of our outstanding common stock effected on May 8, 2015
|
2015-12-31 |
| 2015-11-05 | 4408.32 | 未披露 | 定期报告 | 2015-10-30 |
| 2015-11-05 | 4393.11 | 未披露 |
更多>>
from December 31, 2014 to September 30, 2015
Preferred stock conversion to common stock upon the IPO (unaudited)
Issuance of common stock upon the IPO, net of issuance costs of $9,801 (unaudited)
Exercise of stock options (unaudited)
The 1-for-4 reverse split of our outstanding common stock effected on May 8, 2015
|
2015-09-30 |
| 2015-08-11 | 4358.17 | 未披露 |
更多>>
from December 31, 2014 to June 30, 2015
Preferred stock conversion to common stock upon the IPO (unaudited)
Issuance of common stock upon the IPO, net of issuance costs of $9,887 (unaudited)
Exercise of stock options (unaudited)
The 1-for-4 reverse split of our outstanding common stock effected on May 8, 2015
|
2015-06-30 |
| 2015-06-25 | 4358.17 | 未披露 | 定期报告 | 2015-06-17 |
| 2015-05-15 | 4317.53 | 未披露 |
更多>>
1. the 1-for-4 reverse split of our outstanding common stock effected on May 8, 2015
2. the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 32,901,280 shares of common stock effective upon the closing of this offering, including the conversion of all outstanding shares of our existing preferred stock (other than our Series D preferred stock) into 23,385,029 shares of common stock and the conversion of all outstanding shares of our Series D preferred stock into 9,516,251 shares of common stock based on our capitalization as of December 31, 2014 and an initial public offering price of $8.00 per share;
|
2015-05-15 |
| 2015-06-25 | 207.78 | 10336.24 | 定期报告 | 2015-03-31 |
| 2015-04-30 | 207.40 | 10336.24 |
更多>>
From December 31, 2013 to December 31, 2014
Preferred stock reclassification
Issuance of preferred stock, net of issuance costs of $194
Exercise of stock options
|
2014-12-31 |
| 2015-02-17 | 826.56 | 10336.24 | 定期报告 | 2014-09-30 |
From June 30, 2025 to September 30, 2025
Issuance of shares related to employee stock purchase plan
From June 30, 2024 to September 30, 2024
Issuance of shares related to employee stock purchase plan
From December 31, 2022 to December 31, 2023
Issuance of shares related to March 2023 pre-funded warrants exercise
Issuance of shares related to reverse stock split
Issuance of shares related to August 2022 pre-funded warrants exercise
Issuance of shares related to March 2023 PIPE
Issuance of shares related to employee stock purchase plan
From June 30, 2023 to September 30, 2023
Issuance of shares related to employee stock purchase plan
From March 31, 2023 to June 30, 2023
Issuance of shares related to March 2023 pre-funded warrants exercise
Issuance of shares related to reverse stock split
On February 27, 2023, Arcadia Biosciences, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-40 reverse stock split of the outstanding shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), effective as of 12:01 a.m. (Delaware time) on March 1, 2023 (the “Reverse Stock Split”).
From June 30, 2022 to September 20, 2022
Issuance of shares related to August 2022 Offering
Issuance of shares related to employee stock purchase plan
1.Common Stock offered 2,450,000 shares of common stock
2.Unless the company indicate otherwise, all information in this prospectus is based on 22,192,960 shares of common stock outstanding as of August 12, 2022
From December 31, 2020 to December 31, 2021
Issuance of shares related to the January 2021 PIPE
Issuance of shares at closing of Arcadia Wellness acquisition
Issuance of shares related to exercise of Service and Performance Warrants
From June 30, 2021 to September 30, 2021
Issuance of shares related to employee stock purchase plan
Issuance of shares related to exercise of Service and Performance Warrants
From March 31, 2021 to June 30, 2021
Issuance of shares at closing of Arcadia Wellness acquisition
From December 31, 2020 To March 19, 2021
Issuance of shares related to the January 2021 PIPE
Issuance of shares related to employee stock purchase plan
1.Common Stock offered by this prospectus supplement 2,618,658 shares of Common Stock.
2.Unless the company indicate otherwise, all information in this prospectus is based on 10,832,203 shares of Common Stock outstanding as of December 18, 2020.
From June 30, 2020 to September 30, 2020
Issuance of shares related to exercise of March 2018 PIPE
Issuance of shares related to employee stock purchase plan
Shares of common stock issued at closing of ISI transaction
From March 31, 2020 to June 30, 2020
Issuance of shares related to exercise of June 2018 Warrants
From December 31, 2019 to March 18, 2020
Issuance of shares related to employee stock purchase plan
from December 31, 2018 to September 30, 2019
Issuance of shares related to employee stock purchase plan
Issuance of shares related to employee stock option exercises
Issuance of shares related to June 2019 Offering
Issuance of shares related to the exercise of warrants issued with the June 2019 offering
Issuance of shares related to September 2019 Offering
from December 31, 2018 to June 14, 2019
Issuance of shares related to employee stock purchase plan
Issuance of shares related to June 2019 Offering
From December 31, 2018 to March 7, 2019
Issuance of shares related to employee stock purchase plan
from December 31, 2017 to December 19, 2018
Issuance of shares related to employee stock option exercises
Issuance of shares related to employee stock purchase plan
Issuance of shares related to Purchase Agreement
Issuance of shares related to June Offering
Issuance of shares related to reverse stock split
from December 31, 2017 to September 30, 2018
Issuance of shares related to employee stock option exercises
Issuance of shares related to employee stock purchase plan
Issuance of shares related to Purchase Agreement
Issuance of shares related to June Offering
Issuance of shares related to reverse stock split
From December 31, 2017 to June 30, 2018
Issuance of shares related to employee stock option exercises
Issuance of shares related to employee stock purchase plan
Issuance of shares related to Purchase Agreement
Issuance of shares related to June Offering
Issuance of shares related to reverse stock split
From December 31, 2017 to March 30, 2018
Issuance of shares related to employee stock option exercises
Issuance of shares related to employee stock purchase plan
Issuance of shares related to securities purchase agreement
Issuance of shares related to reverse stock split
from December 31, 2016 to January 24, 2018
Issuance of shares related to employee stock purchase plan
Exchange of membership interest in unconsolidated entity for common stock
On Janaury19, 2018, Arcadia Biosciences, Inc. held a special meeting of stockholders. At the Special Meeting, the stockholders approved the proposal to amend the Company’s Amended and Restated Certificate of Incorporation, as amended , to effect a reverse stock split of its outstanding common stock at a ratio in the range of one-for-ten to one-for-twenty, to be determined at the discretion of the Board of Directors of the Company.
From December 31, 2015 to December 31, 2016
Exercise of stock options
Issuance of shares related to employee stock purchase plan
From December 31, 2014 to December 31, 2015
Exercise of stock options
Preferred stock conversion to common stock upon the IPO
Issuance of common stock upon the IPO, net of issuance costs of $9,799
The 1-for-4 reverse split of our outstanding common stock effected on May 8, 2015
from December 31, 2014 to September 30, 2015
Preferred stock conversion to common stock upon the IPO (unaudited)
Issuance of common stock upon the IPO, net of issuance costs of $9,801 (unaudited)
Exercise of stock options (unaudited)
The 1-for-4 reverse split of our outstanding common stock effected on May 8, 2015
from December 31, 2014 to June 30, 2015
Preferred stock conversion to common stock upon the IPO (unaudited)
Issuance of common stock upon the IPO, net of issuance costs of $9,887 (unaudited)
Exercise of stock options (unaudited)
The 1-for-4 reverse split of our outstanding common stock effected on May 8, 2015
1. the 1-for-4 reverse split of our outstanding common stock effected on May 8, 2015
2. the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 32,901,280 shares of common stock effective upon the closing of this offering, including the conversion of all outstanding shares of our existing preferred stock (other than our Series D preferred stock) into 23,385,029 shares of common stock and the conversion of all outstanding shares of our Series D preferred stock into 9,516,251 shares of common stock based on our capitalization as of December 31, 2014 and an initial public offering price of $8.00 per share;
From December 31, 2013 to December 31, 2014
Preferred stock reclassification
Issuance of preferred stock, net of issuance costs of $194
Exercise of stock options